Effects on bone mass of oral alendronate, hormone replacement therapy and combined regimens in post-menopausal women. Report on the short term effects from a comparative study;Efectos del alendronato oral, la hormonoterapia de reemplazo y la combinacion de ambos sobre la masa osea en mujeres posmenopausicas. Informe preliminar de un estudio comparativo

Medicina

Volumn 57, Issue SUPPL. 1, 1997, Pages 49-55

  Ulla, Maria R ^a,b   Araujo, Graciela L ^a   Giglione, Fabiana ^a   Fajreldines, Flaviana ^a   Domingo, Patricia ^a   Noriega, Roberto ^a   Rivoira, Maria A ^a  

^a Centra Privado Endocrinol O   (Argentina)

^b CEO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ESTRADIOL; MEDROXYPROGESTERONE; OSTEOCALCIN; PYRIDINOLINE;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; FEMALE; FEMUR NECK; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; TRANSDERMAL DRUG ADMINISTRATION;

AGED; ALENDRONATE; ANALYSIS OF VARIANCE; BONE DENSITY; BONE DISEASES, METABOLIC; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDROXYPROGESTERONE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0030798482     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Consensus Development Conference: Diagnosis, Prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-50.
2. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Int Med 1995; 122: 9-16.
3. Sagraves R. Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. J Clin Pharmacol 1995; 35 (sup): 2S-10S.
4. Garton M, Reid D, Rennie E. The climacteric, osteoporosis and hormone replacement; views of women aged 45-49. Maturitas 1995; 21: 7-15.
5. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996; 18: 141-50.
6. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43.
7. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995; 99: 36-42.
8. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Ginebra, 1994.
9. Majeska RJ, Ryaby JT, Einhorn TA. Direct modulation of osteoblastic activity with estrogen. J Bone Joint Surg 1994; 76-A: 713-21.
10. Roldán EJA, Kerzberg EM, Castelli A, Pérez Lloret A. Efecto de bajas dosis de pamidronato (APD) oral sobre la calcemia de pacientes osteopénicas u osteoporóticas. Medicina (Buenos Aires) 1996; 56: 133-7.
11. Fleisch, H. Bisphosphonates in bone disease. From the laboratory to the patient. NY: Parthenon Publishing Group Ltd., Carnforth, 1995.
12. Garnero P, Gineyts E, Arbault P, et al. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995; 10: 641-9.
13. Ferretti JL, Cointry G, Capozza R, Montuori E, Roldán E, Pérez Lloret A. Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxy-propylidene)-1, 1-bisphosphonate (APD) on femur diaphysis and cortical bone tissue in rats. Bone Miner 1990; 11: 111-22.
14. Cointry GR, Mondelo N, Zanchetta JR, Montuori E, Ferretti JL. Intravenous olpadronate restores ovariectomy-affected bone strength. A mechanical, densitornetric and tomographic (pQCT) study. Bone 1995; 17 (supl): 373S-378S.
15. Guy JA, Shea M, Peter C. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 1993; 53: 283-8.
16. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333. 1437-43.